Introduction
Final adult height and body composition are maintained in a constant interval for each given species. Somatototrophs, the pituitary cells secreting growth hormone (GH), are specialized secretory cells. However, they are not terminally differentiated: the pituitary retains some plasticity throughout life, enabling appropriate responses to events such as puberty and pregnancy (Melmed, 2003) . Somatotrophs play a key role in the control of growth during infancy and puberty, although they continue to secrete GH throughout adult life. Somatotroph number and function are tightly regulated, as GH hypersecretion leads to excessive growth in the form of either gigantism or acromegaly. Genetic factors leading to somatotroph hypoplasia are well known, but little is known about the mechanisms controlling physiological adjustments in somatotroph number. In this connection, the incidence of pituitary somatotroph adenomas is surprisingly low (about 3-4 cases per 10 6 per year) compared with adenomas of other endocrine glands (Holdaway and Rajasoorya, 1999) . More puzzling still is the consistent benignity of these tumors, which never metastasize (Melmed, 2003; Kaltsas et al, 2005) .
We have recently demonstrated that somatotrophs are the only pituitary secretory cells expressing Ret, GDNF and GFRa1, both in humans (Japon et al, 2002) and in rats (Urbano et al, 2000) . This expression pattern is maintained in all somatotroph adenomas. Ret is a transmembrane receptor well known for its differentiation-and survival-controlling functions in epithelial cells, neurons and neuroendocrine cells. Alternative splicing produces two main isoforms: Ret long (Ret-L or Ret51), 1072 amino acids (aa) long, and Ret short (Ret-S or Ret9), 1114 aa long, with different sequences in the C-terminal region (51 aa long in Ret-L and 9 aa long in Ret-S) (Tahira et al, 1990) . Ret has four coreceptors (GFRa1, 2, 3 and 4), with ligands GDNF, NTN, ART and PSP, respectively. Extensive research on Ret function in mammals indicates that it has two main functions. First, it actively promotes survival, growth and extension/migration of cells such as neurons (neurite and axonal sprouting) and epithelial renal cells (branching). In these roles, Ret binds to its ligand GDNF and its GPI-anchored extracellular coreceptor GFRa1, and this binding induces the tyrosine kinase activity of Ret, triggering various signal transduction pathways Porter and Dhakshinamoorthy, 2004; Arighi et al, 2005) . Second, Ret appears to induce apoptosis, but only in the absence of GDNF; to date, however, this effect has only been demonstrated in transient transfection of HEK293T and neuroblastoma cell lines (Bordeaux et al, 2000) . In line with this, Ret has been included in the family of 'dependence receptors', together with p75NTR, DCC, UNC5H, PTC1 and the androgen receptor. In humans, mutations that activate Ret lead to multiple endocrine neoplasia type 2 (MEN 2), whereas inactivating mutations lead to Hirschprung's disease (Santoro et al, 2004; Arighi et al, 2005) .
Here, we report a study of Ret functions in a somatotroph cell line and in primary pituitary cultures. We uncover a pathway in which Ret, in the absence of GDNF, induces Pit-1 overexpression, leading to increased p53 expression and apoptosis. We identify the kinases involved in the induction G), in contrast with the previous findings in HEK cells. Basal levels of activated caspase 3 were present in the GH4C1 cells, and caspase-3 activity was strongly induced by Ret transfection and reduced by GDNF or zVAD; that is, the effects on caspase 3 paralleled the effects on apoptosis, IC-Ret presence and Pit-1 level (Figure 1F, G and B, E) .
In the presence of GDNF, Ret forms a heterodimeric complex with GDNF and GFRa1, activating Ret's tyrosine kinase activity (so that it phosphorylates susceptible cytoplasmic substrates). We therefore investigated whether the tyrosine kinase activity of Ret is necessary for induction of apoptosis and/or of Pit-1 expression. The kinase-dead mutants of Ret-L (Ret-L KR , K758R substitution) and Ret-S (Ret-S KR , K758R substitution) were transiently transfected into GH4C1 cells. The transfected cells did not show increased tyrosine kinase activity in the presence of GDNF (unlike cells transfected with Ret-L or Ret-S) ( Figure 2B ), although Ret was expressed to similar levels ( Figure 2C ). While all Ret isoforms had apoptotic effects, the protective effects of GDNF were not seen in the cells transfected with the kinase-dead mutants ( Figure 2D ). Interestingly, both kinase-dead Ret isoforms strongly induced Pit-1 mRNA and protein expression (like the normal isoforms), but, unlike in cells transfected with the normal isoforms, GDNF did not inhibit this response ( Figure  2E and F); again, this is in line with a relationship between Ret's apoptotic activity and its induction of Pit-1 expression.
Given our results showing that Ret's apoptotic activity is associated with caspase-3 processing and the appearance of the intracytoplasmic fragment IC-Ret, we transfected cells with Ret-S DN , a Ret-S mutant with a D707N substitution affecting the first caspase-3 consensus site in the cytoplasmic tail of the receptor ( Figure 2A ). As previously demonstrated (Bordeaux et al, 2000) , transfected Ret-S DN could not be processed by caspase 3 in vivo, and no IC-Ret band was detected in Western blotting ( Figure 2G ). Ret-S DN did not induce either apoptosis ( Figure 2H ) or Pit-1 mRNA or protein expression ( Figure 2I and J).
Ret-induced apoptosis is mediated by Pit-1, and Pit-1 overexpression increases p53 levels The data shown in Figures 1 and 2 suggested a direct relationship between caspase-3-processed intracytoplasmic Ret, Pit-1 expression and apoptosis. The time course of caspase-3 activity in extracts of transfected cells showed that the maximal activity was reached immediately after initiating the Ret transfection (2 h) ( Figure 3A) . Coincidentally, the induction of Pit-1 expression in somatotrophs was a very early event, seen as soon as 2 h after Ret transfection ( Figure 3B ), and maintained throughout the experiment ( Figure 3C ). Ret also induced a marked increase in p53 at 24 h after transfection ( Figure 3D ) before the induction of apoptosis, which peaked around 48 h after transfection (see Figures 1 and 2 ). Incubation with zVAD (which blocked IC-Ret generation, induction of Pit-1 expression and apoptosis; Figures 1B, E and G) also blocked the p53 increase ( Figure 3E ).
This sequence of events suggested that Ret-induced apoptosis in somatotrophs is mediated by Pit-1 induction. Transfection of a Pit-1 expression construct induced similar levels of apoptosis to Ret transfection, and the two treatments were not additive ( Figure 3F ). However, Pit-1-induced apoptosis was blocked by GDNF ( Figure 3G ), simultaneously with the inhibition of transfected Pit-1 expression (Supplementary Figure 2A) . To confirm that Pit-1 expression is essential for Ret-induced apoptosis, we used Pit-1 siRNA to block basal and Ret-induced Pit-1 expression ( Figure 3H ). The presence of Pit-1 siRNA entirely blocked the apoptosis induced by transfection with Ret-L, Ret-S or Pit-1 ( Figure 3I ), and also blocked p53 induction ( Figure 3J ). These results suggest that caspase-3-processed IC-Ret induces Pit-1 expression, which in turn increases p53 expression and causes apoptosis. Ret-induced c/EBPa binding to the Pit-1 promoter depends on PKCd, JNK and CREB Next, we performed experiments designed to identify kinases involved in the induction of Pit-1 expression by Ret. Sustained p-JNK and p-CREB expressions were detected in somatotrophs transfected with all Ret isoforms and mutants that induced apoptosis, but not in somatotrophs transfected with the non-apoptosis-inducing mutant Ret-S DN ( Figure 4A ). As previously described (Chiariello et al, 1998; Feng et al, 1999; Poteryaev et al, 1999; Trupp et al, 1999; Hayashi et al, 2000; Pezeshki et al, 2001 ), short-term (15 min) treatment with GDNF also induced p-JNK or p-CREB activation ( Figure 4B ) that returned to basal levels after 30 min (Supplementary Figure 2B ) and was not altered by Ret expression. However, long-term (24 h) treatment with GDNF, which blocks Ret-induced apoptosis, also blocked the Ret-induced p-JNK and p-CREB sustained expression ( Figure 4C ). Likewise, we investigated whether PKCd is activated by Ret. PKCd has been implicated in apoptosis induced by DNA-damaging agents or Fas ligand: after its induction, PKCd is phosphorylated (p-PKCd) and processed, and the free catalytic domain migrates to the nucleus inducing apoptosis (DeVries et al, 2002; Mecklenbrauker et al, 2002 Mecklenbrauker et al, , 2004 , although the mechanism remains unknown. p-PKCd was detected in somatotrophs transfected with the apoptosis-inducing Ret forms, but not in cells transfected with Ret-S DN ( Figure 4D ). In contrast to the effects on JNK or CREB, short-term treatment (15 min) with GDNF reduced p-PKCd levels in cells transfected with Ret-L and Ret-S but not in cells transfected with the kinase-dead mutant Ret-L KR ( Figure 4D ). This reduction in p-PKCd levels by GDNF was maintained after 24 h of treatment, coinciding with the Figure 4C ). Retinduced p-PKCd production was also blocked by the caspase inhibitor zVAD ( Figure 4E ). These results suggested that Ret may induce Pit-1 and apoptosis through activation of PKCd. Rottlerin, a PKCd inhibitor, blocked PKCd phosphorylation by all the apoptosis-inducing Ret forms ( Figure 4F ). Rottlerin also blocked Ret-induced p-JNK expression but not Retinduced p-CREB expression ( Figure 4G ). Rottlerin strongly reduced Ret-dependent Pit-1 expression, and in line with this reduced Ret-induced apoptosis; however, it did not affect Pit-induced apoptosis ( Figure 4H and I). Finally, killer CREB, a dominant-negative form of CREB, significantly reduced Ret-induced apoptosis ( Figure 4H ). These data suggest a two-branched pathway for Ret-induced Pit-1 expression, one branch dependent on activation of PKCd/JNK and the other dependent on activation of CREB. Pit-1 mRNA induction by this pathway was very rapid, suggesting a transcriptional effect. The most important consensus binding sites on the rat Pit-1 promoter are shown in Figure 4J . Both CRE elements are essential for GHRH-and ghrelin-induced Pit-1 expression (Soto et al, 1995; Garcia et al, 2001) . In somatotrophs cotransfected with Ret and promoter/Luc constructs with decreasing promoter length, luciferase activity was detected with the À2500, À959 and À358 promoter fragments (strongest activity with the À358 fragment), whereas further shortening to À231 abolished the Ret-dependent activity ( Figure 4J ). Luciferase activity was also completely abolished by treatment with GDNF or by cotransfection with Ret-S DN instead of Ret-S ( Figure 4K ). Luciferase activity in cells cotransfected with Ret-S and the À358 promoter fragment was markedly reduced by rottlerin and by killer CREB, and completely abolished by adding both together, confirming the additive effects of the PKCd/JNK and CREB pathways ( Figure 4L ). These results indicate that the Ret-responsive region of the rat Pit-1 promoter lies between this protein's positions À358 and À231. A consensus binding site for the Pit-1 transcription factor c/EBPa appears near the first CRE, just before À231. Interestingly, the human Pit-1 promoter has a similar conserved site located upstream to the TATA region (Pfaffle et al, 1992) , and initial results corroborate a Ret-dependent regulation of the hPit-1 promoter (data not shown). To confirm that Ret induces binding of c/EBPa to the rat Pit-1 promoter, we used chromatin immunoprecipitation (ChIP) assay with c/EBPa-specific antibodies, followed by PCR using primers for a small region of the Pit-1 promoter, including the c/EBPa binding site. A basal level of c/EBPa binding was detected in untransfected cells, and an increase in this binding in Ret-transfected cells was detected within only 4 h of transfection. The increase in c/EBPa binding was completely abolished by GDNF and significantly reduced by rottlerin or cotransfection with killer CREB ( Figure 4M ).
The intracytoplasmic portion of Ret forms a complex with caspase 3 and PKCd
Our data suggested a strong relationship between the intracellular Ret portion, caspase 3, PKCd, Pit-1 expression and apoptosis. It seemed that blockage of Ret or caspase-3 processing also inhibited Pit-1 expression. In fact, caspase-3 activity was detected as early as 2 h after transfection of either Ret-S, the kinase-dead mutant Ret-S KR or the intracellular portion of Ret (IC-Ret 707-1017 ). However, there was no caspase-3 activity after transfection with Ret-S DN , a mutant that could not be processed by caspase-3 ( Figure 5A , upper panel). GDNF was able to block Ret-induced caspase-3 activity, Pit-1 and apoptosis, but could not stop the apoptosis induced by IC-Ret 707-1017 , which correspondingly induced Pit-1 expression ( Figure 5A , lower panels). We have found another caspase-3-processed protein, PKCd (Voss et al, 2005) , implicated in the pathway from Ret to the Pit-1 promoter.
As both the catalytic fragment of PKCd and caspase 3 have been located in the nucleus, we investigated the location of the processed intracellular fragment of Ret. Both the fulllength Ret-S and the fragment IC-Ret 707-1017 transfected in GH4C1 showed cytoplasmic location ( Figure 5B and Supplementary Figure 2D ). As it has been demonstrated that PKCd binds to and phosphorylates caspase 3 in monocytes (Voss et al, 2005) , we investigated whether IC-Ret binds either of these proteins. Initial experiments showed the presence of PKCd in Ret immunoprecipitates, with a weak band around 80 kDa and a stronger band around 40 kDa (data not shown); straight Western blotting against PKCd showed the 80-kDa band and a shorter (unphosphorylated) band around 60 kDa ( Figure 5C , right). We thought that the smaller 40-kDa band that appeared in the Ret immunoprecipitates could be the processed/phosphorylated catalytic fragment of PKCd, absent in the 60-kDa band. Therefore, we performed IP-Ret IP followed by Western blotting against phosphorylated PKCd ( Figure 5C , upper left). Full-length Ret-S and IC-Ret 707-1017 both co-immunoprecipitated with the p-PKCd; the strongest band was the processed 40-kDa band of p-PKCd and the weakest band was the full-length 80-kDa p-PKCd. Formation of this Ret/p-PKCd complex was prevented in the presence of the ligand GDNF. The Ret-S DN mutant was not able to associate with p-PKCd, in line with its inability to induce Pit-1 expression or apoptosis. In the absence of GDNF, full-length Ret-S and IC-Ret 707-1017 also co-immunoprecipitated with unprocessed (32 kDa) or processed (20/19 kDa) caspase 3 ( Figure 5C , lower left). However, Ret-S DN associated very weakly with unprocessed caspase 3, in keeping with its inability to induce caspase-3 processing/activation. To further study this complex, we immunoprecipitated PKCd and assessed its association with either caspase 3 or the intracellular portion of Ret. The presence of any Ret construct, even Ret-S DN , induced the formation of the PKCd/ full-length caspase-3 complex, albeit in residual amounts in the presence of GDNF ( Figure 5D , lower left). However, ICRet was found to be associated with PKCd only in the presence of Ret-S or IC-Ret 707-1017 ( Figure 5D, upper left) , that is, the same samples in which PKCd was associated with Ret (compare upper panels of Figure 5C and D). These results indicated that the intracellular portion of Ret induces the formation of a complex with both full-length caspase 3 and PKCd that results in cleavage (and activation) of the trio, and suggested that the complex was unstable when Ret could not be processed (Ret S DN ), or when GDNF induced Ret dimerization and tyrosine kinase activation.
GDNF prevents Ret-induced Pit-1 expression and apoptosis through Akt activation in both the somatotroph line and in primary pituitary cultures Many pathways induced by GDNF have been described, both in the presence (Chiariello et al, 1998; Feng et al, 1999; Hayashi et al, 2000; Santoro et al, 2004; Arighi et al, 2005) and absence (Poteryaev et al, 1999; Trupp et al, 1999; Pezeshki et al, 2001 ) of Ret. In neurons, the blocking of Ret-induced apoptosis by GDNF is mediated by the kinase Akt: specifically, a GDNF/GFRa1/Ret complex induces PI3K activation, leading to Akt phosphorylation and activation (Besset et al, 2000; De Vita et al, 2000; Hayashi et al, 2000) . We therefore investigated whether this same pathway acts in somatotrophs. GDNF strongly induced Akt phosphorylation in cells transfected with wild-type Ret, but not in cells transfected with the kinase-dead mutants Ret-L KR or Ret-S KR (Supplementary Figure 2C) . The PI3K inhibitor LY294002 partially reduced the GDNF-induced phosphorylation of Akt ( Figure 6A) . Likewise, the blocking of Ret-induced apoptosis ( Figure 6B ) and Pit-1 expression ( Figure 6C ) by GDNF was abolished by coincubation with LY294002.
We next investigated whether the results obtained in the GH4C1 somatotroph line were reproduced in primary pituitary cultures expressing endogenous Ret receptors. Pituitary cultures were grown in collagen-IV-coated dishes. Around 30% of cells were somatotrophs, in line with the high proportion of somatotrophs seen in vivo, and 99.9% were GH and Ret positive ( Figure 6D) ; note that somatotrophs are the only cells expressing Ret and GFRa1 (Urbano et al, 2000; Japon et al, 2002; and Supplementary Figure 3) in the rat and human pituitary. After 2 days, the original medium (containing 10% FCS) was changed to serum-deprived medium (only (Carneiro et al, 1998; Garcia et al, 2001 ) (inside boxes) and putative (outside boxes) response elements. Cells were cotransfected with Ret plus Pit-1 promoter-luciferase constructs with increasing deletions of the promoter. In the presence of Ret-S, Pit-1 promoter deleted to À2500 showed a three-fold induction in luciferase activity that was enhanced with further deletions, especially to À358, but that was lost with further deletion to À231. (K) The À358 bp region appears to be very important for the response to Ret, as the response was blocked by GDNF treatment and could not be induced by the Ret-S DN . (L) Both rottlerin and kCREB reduced Pit-1 promoter induction by Ret, although complete abolishment could only be achieved with both inhibitors together. (M) A consensus c/EBPa site was present in this small region of the promoter. Specific binding of c/EBPa to the Pit-1 promoter could be demonstrated by ChIP only 4 h after transfection with Ret. This was abolished by GDNF treatment and reduced by treatment with rottlerin or kCREB. c/EBPa Western blotting showed both the 42 and 30-kDa isoforms present in pituitary cell lines (Schaufele, 1996) . 0.5% FCS). Serum deprivation induced massive apoptosis and c/EBPa, Pit-1 and p53 overexpression that could be blocked by addition of GDNF, which blocked also IC-Ret expression ( Figure 6D ). In line with our findings in GH4C1, short-term GDNF treatment induced phosphorylation of Akt and CREB, but not of other kinases such as ERK. Treatment with the somatotroph-specific factors GHRH or ghrelin (both known to induce a short-term increase in Pit-1 expression; Soto et al, 1995; Garcia et al, 2001) likewise induced phosphorylation of Akt ( Figure 6E ). These results indicate that Akt is a key mediator in Pit-1 induction to prevent apoptosis, controlling its time course. Long-term treatment of the cultures with GDNF reduced p-CREB, p-JNK and p-PKCd expression ( Figure 6E ). Either Pit-1 or Ret siRNA transfection of the cultures completely blocked the apoptosis or the Pit-1 expression ( Figure 6F ), indicating a role of Ret in maintenance of the somatotroph phenotype in adult pituitary.
Activation of the Ret/Pit-1/p53/apoptosis pathway in vivo prevents tumor growth
The above results indicated that the apoptotic pathway in primary pituitary cultures is the same as in the GH4C1 line. To investigate whether this pathway acts in vivo, we analyzed the pituitaries of 20 d.p.c. Ret KO mice in comparison with their wild-type littermates. Ret KO mice die around the first day of life owing to the absence of kidney (Schuchardt et al, 1994) . Coronal and sagittal (data not shown) sections of the heads were obtained every 5 mm. was significantly larger than in the wild type (P ¼ 0.007; Figure 7D ), as was AP area (P ¼ 2.4 Â 10
À5
; Figure 7E ), whereas IL and NP volumes and areas were similar to those of the wild type. To rule out bias in the different sections, we calculated the ratios of AP to IL area and NP to IL area for each section. The AP/IL ratio was 1.4 times greater in the Ret KO mice (P ¼ 0.009), whereas the NP/IL ratio showed no difference from the wild type (P ¼ 0.38; Figure 7F ).
There are five different types of secretory cell in the adenopituitary: somatotrophs (producing GH), lactotrophs (PRL) and thyrotrophs (TSH) are Pit-1-expressing cells derived from a common precursor, whereas gonadotrophs (LH and FSH) and corticotrophs (ACTH) are Pit-1 negative. Gonadotrophs (LH, FSH) also express a specific nuclear transcription factor called SF-1 (Morohashi and Omura, 1996) . Whereas Pit-1-positive nuclei showed increased abundance in Ret KO mice (P ¼ 0.0097), the number of SF-1-positive nuclei was similar in the two groups of mice (P ¼ 0.98; Figure 7G ). We counted the different Pit-1-positive lineages. Ret KO mice presented more GH-producing cells per hemipituitary (P ¼ 9.8 Â10
À6
), whereas the number of TSH-producing cells was slightly, although not significantly, decreased (P ¼ 0.09), and the number of PRL-producing cells was similar to that in wild type (P ¼ 0.92). The total number of GH-, TSH-and PRL-producing cells in the wild-type pituitary equalled the number of Pit-1-positive cells. In the Ret KO mice, however, a subset of Pit-1-positive cells were not stained for any hormone marker, suggesting a delay in differentiation. Therefore, as GH cells are the only cells expressing Ret in the normal pituitary, somatotroph hyperplasia seems to have been the main cause of the larger size of the Ret KO pituitaries. There was no difference between the two groups in proliferative index in the pituitary, as measured by BrdU staining ( Figure 7C and H) ; similar results were found by Ki-67 staining (data not shown). We conclude that somatotroph hyperplasia in Ret KO mice is likely due to enhanced survival through the differentiation process.
To investigate whether the most important feature of the pathway in vivo is Pit-1 expression or GH phenotype, we engineered the overexpression of Ret in Ret-negative/Pit-1-expressing pituitary lactotrophs, and then looked for increased Pit-1 expression, increased p53 expression and apoptosis. We used a retrovirus bearing the human Ret-S . In these cultures, change from DMEM þ 10% FCS to serum-deprived medium (DMEM þ 0.5% FCS) induced marked apoptosis and IC-Ret, c/EBPa, Pit-1 and p53 expression. All of them could be rescued by GDNF.
(E) Short-term treatment (15 min) of primary cultures with Pit-1 regulators (ghrelin, GDNF or GHRH) induced phosphorylation of CREB and Akt, whereas phosphorylation of ERK was induced only by GHRH (Pombo et al, 2000) . Ghrelin and GHRH (Soto et al, 1995; Garcia et al, 2001) induced increased Pit-1 mRNA expression over a period of about 2 h, whereas GDNF reduced Ret-induced Pit-1 mRNA expression. As in the GH4C1 cell line, prolonged treatment with GDNF in primary cultures blocked the expression of p-CREB, p-JNK and p-PKCd. (F) Both Pit-1 and Ret siRNA abolished Ret-induced Pit-1 protein expression after serodeprivation in primary cultures, in parallel with prevention of apoptosis (**Po0.01; ***Po0.001).
cDNA (LPC-Ret) or the empty construct (LPC). For retroviral expression, we needed actively dividing cells, and so we used estrogen-induced lactotroph hyperplasia (Tsukahara et al, 1994) . The LPC or LPC-Ret retrovirus was delivered to estrogen-injected female rats by stereotaxic injection. One week later, the pituitaries were dissected out, weighed and processed. Estrogens induced a strongly significant increase in pituitary weight in LPC-infected rats by comparison with nontreated controls (P ¼ 0.00019). Infection with the Ret-expressing retrovirus prevented this estrogen-induced hyperplasia (LPC þ E2 versus LPC-Ret þ E2 P ¼ 0.00077, LPC-Ret þ E2 versus control P ¼ 0.34) ( Figure 8A and Supplementary Figure 4C ). In line with this, PRL immunostaining was much weaker in LPC-Ret-infected pituitaries than in LPCinfected pituitaries; however, the small areas that showed detectable PRL staining in LPC-Ret-infected pituitaries also Of the three Pit-1-positive cell types, only GH were more abundant; no difference was detected in TSH or PRL abundance. Likewise, we did not detect any difference in the abundance of BrdU-positive cells (**Po0.01; ***Po0.001).
showed strong Ret costaining ( Figure 8B ). The estrogentreated LPC-Ret-infected pituitaries contained detectable levels of IC-Ret and increased amounts of Pit-1, p53, p-CREB and p-JNK by comparison with both estrogen-treated LPC-infected pituitaries and untreated pituitaries. Cleaved PARP (80 kDa) was only present in LPC-RET-infected pituitaries ( Figure 8C ). Some pituitaries were dissected out just 24 h after retroviral delivery, when no marked alteration in lactotroph numbers was expected. Figure 3A) . p-PKCd, IC-Ret, Pit-1 and p53 levels were increased within 24 h of LPC-RET infection.
Phosphorylated c/EBPa levels were increased in LPC-Retinfected pituitary, whereas active caspase-3 levels, reduced in LPC-infected pituitary, returned to control levels (Supplementary Figure 3B) . Taken together, these results demonstrate that Ret expression blocks estrogen-induced lactotroph hyperplasia in vivo by the same mechanism as revealed in the GH4C1 somatotroph cell line and in primary pituitary cultures, that is, via Pit-1 overexpression leading to increased p53 expression and thus apoptosis.
Discussion
Dependence receptors like Ret only induce apoptosis in the absence of a particular ligand, so that cell survival depends on the presence of the ligand. Besides, it seems likely that these proteins also play key roles in cell differentiation . Our present results rule out the possibility that Ret is necessary for differentiation to the somatotroph fate, and establish that Ret's role in the pituitary is to regulate Pit-1 expression and control survival of differ- entiated somatotrophs ( Figures 6F and 7A-C) . We might speculate that this acts as a mechanism to prevent excessive body growth. For apoptotic effect, dependence receptors need to be intracellularly processed by proteases, releasing a fragment with apoptotic properties. It remains unclear which specific protease processes each receptor . We found processing of the Ret receptor to be caspase-dependent, both in cell cultures and in vivo. It has been postulated that initial processing of Ret takes place under low levels of caspase-3 activation, which induces greater caspase activation in an activating loop . In somatotrophs, the maximal caspase-3 activity was detected immediately after Ret transfection (Figures 3 and 5) , with the caspase-3 processing Ret intracellularly (to IC-Ret) in the absence of GDNF, and inducing sustained activation of PKCd, JNK, c/EBPa and CREB, leading to strong and sustained overexpression of Pit-1, which in turn led to increased p53 expression and apoptosis. By contrast, GDNF activated Ret's tyrosine kinase activity, leading to Akt activation, and thus reduced Pit-1 expression, promoting survival ( Figure 6B ). Long-term phosphorylation of either CREB or JNK seems to be the key to the Ret-induced process, as GDNF inducing short-term phosphorylation of both has opposite effects (Chiariello et al, 1998; Feng et al, 1999; Poteryaev et al, 1999; Trupp et al, 1999; Hayashi et al, 2000; Pezeshki et al, 2001) . Recently, the UNC5H2 dependence receptor has been found to bind and activate DAP kinase to induce apoptosis (Llambi et al, 2005) . We provide evidence that the intracellular portion of Ret forms a complex with PKCd and caspase 3 ( Figure 5 ) and binding of caspase 3 and PKCd has been described previously (Voss et al, 2005) . Ternary complex formation was dependent solely on the presence of Ret, even an inactive form ( Figure 5D ), but was not enough to initiate the activation of the complex. Our data suggest that after binding to the complex, IC-Ret initiates the processing and activation of both PKCd and caspase 3. A certain basal level of activated caspase 3 could initiate Ret cleavage and thus trigger an activating loop (Llambi et al, 2005) ; alternatively, the presence of the monomeric Ret cytoplasmic tail may elicit formation of the ternary complex in which caspase 3 would become stabilized and activated. We favor this latter model, as total caspase-3 levels are increased by Ret transfection. In contrast to previous findings in HEK cells (Bordeaux et al, 2000) , in somatotrophs, GDNF was able to suppress Ret processing by dimerization of the Ret receptors and Akt recruiting, disrupting the IC-Ret/PKCd/caspase-3 complex.
The PKCd catalytic fragment migrates to the nucleus (DeVries et al, 2002) , but its targets remain unknown. In many systems, PKCd is implicated in apoptosis downstream of p53 but upstream of JNK (Humphries et al, 2006; Liu et al, 2006; Miyamoto et al, 2002) . PKCd-dependent CREB phosphorylation has been described for the B-cell receptor (Blois et al, 2004) . However, in our cells, inhibition of PKCd, although it blocked JNK activation, did not abolish CREB phosphorylation. Our results indicate a cooperative action of c/EBPa and CREB on the Pit-1 promoter. Similar cooperation has been described in human monocyte differentiation (Brenner et al, 2003) . Taken together, our data suggest a model in which, once the ternary complex (IC-Ret/PKCd/ caspase 3) is formed and processed, PKCd either alone or bound to caspase-3 activates JNK. It remains to be determined whether JNK activation occurs in the cytosol or in the nucleus, and how CREB phosphorylation is initiated and maintained independent of PKCd activation.
Previous reports have already suggested a role of c/EBPa in the pituitary (Schaufele, 1996) . Pit-1 establishes somatotroph (GH), lactotroph (PRL) and thyrotroph (TSH) phenotypes during pituitary development. Based on in vitro experiments in lactotroph cell lines, it is currently accepted that Pit-1 has two functions, regulating both differentiation and proliferation (Castrillo et al, 1991) . However, there is no substantial in vivo evidence in rodents or humans to support this latter possibility: the Pit-1 gene is not altered in adenomas, and Pit-1 expression appears to be more closely related to GH secretion than to tumorigenesis (Delhase et al, 1993; Hoggard et al, 1993; Pellegrini et al, 1994) . Moreover, Pit-1 mutations have been found in human hypopituitarism without pituitary hypoplasia (Pfaffle et al, 1992) , whereas no increase in Pit-1 expression is required for in vivo estrogeninduced lactotroph hyperplasia in rats (Tsukahara et al, 1994) . Our data show that too much Pit-1 is deleterious for the somatotroph; conversely, knocking down Pit-1 prevents apoptosis. The apoptosis induced by dependence receptors appears to be independent of both the intrinsic (caspase 9/ Apaf1) and the extrinsic (FADD/caspase 8) pathways (Porter and Dhakshinamoorthy, 2004) . The induction of p53 expression by Pit-1 links Ret-induced apoptosis with p53. To date, the only reported relationship of dependence receptors with p53 is via netrin-1, a ligand that blocks p53-dependent apoptosis by binding to the UNC5B dependence receptor (Tanikawa et al, 2003) .
In the presence of the PI3K inhibitor LY-294002, Ret induced Pit-1 overexpression and apoptosis despite the presence of GDNF, although Akt phosphorylation was not completely abolished. GDNF induces Akt activation through binding of a Gab-p85PI3K complex to the phosphorylated Y1062 of activated Ret, thus preventing apoptosis (Besset et al, 2000; De Vita et al, 2000; Hayashi et al, 2000) . In somatotrophs, the PI3K-Akt pathway seems to be essential for Pit-1 downregulation and cell survival. This pathway could act at various levels: by downregulating Ret processing by caspase inhibition, by decreasing c/EBPa phosphorylation through PP2A activation (Wang et al, 2004) or by regulating p53-dependent apoptosis. The fact that GDNF is not able to block Pit-1 induction/apoptosis induced by transfection of the IC-Ret 707-1017 fragment, but decreases Pit-1 induction of exogenous transfected Pit-1 and consequent apoptosis, suggests that the GDNF action is before the Pit-1 action, and rules out any direct effect on p53; it seems probable that IC-Ret 707-1017 sequesters PI3K/Akt, preventing its activation near the membrane. GDNF (via Akt induction) and siRNA Pit-1 were also able to prevent apoptosis in the primary pituitary culture. GHRH, ghrelin and GDNF share the ability to activate Akt and regulate Pit-1 transcription. GHRH and ghrelin cause very short-lived Pit-1 induction (2 h) (Soto et al, 1995; Garcia et al, 2001) , whereas GDNF reduces Pit-1 transcription. We propose that Akt activation by GHRH and ghrelin switches off the Pit-1 promoter, confining the induction to this short period. In fact, GDNF is able to decrease Pit-1 levels after transfection of exogenous Pit-1 expression vector; in this case, the positive feedback of exogenous Pit-1 activating the endogenous Pit-1 promoter is disrupted by Akt. A role for Akt in pituitary tumorigenesis is suggested by the finding of increased p-Akt levels in pituitary tumors (Musat et al, 2005) .
Our results support the notion of dependence receptors being tumor suppressors (Mazelin et al, 2004) , where Ret, like the other dependence receptors, would be a two-sided tumor regulator: a tumor suppressor because of its dependence receptor activity and an oncogene because of its tyrosine kinase activity. We further show that activation of the Ret/Pit-1/p53 pathway was able to block tumor growth in vivo, probably by the same mechanisms described in cultures. These results raise the possibility of Ret-based therapy as a treatment for conventional Pit-1-expressing chemotherapyresistant adenomas.
The Ret/Pit-1/p53 pathway, conserved in mouse, rat and human somatotrophs, appears to be a mechanism to prevent oversized individuals, exerting a strong pressure on somatotrophs to stay in the pituitary, and limiting their numbers (Supplementary Figure 5) . Disrupting Ret expression during development provokes somatotroph hyperplasia ( Figure 7) ; the final result in the adult animal might perhaps be gigantism. If a precursor cell is to become a somatotroph, it needs Pit-1, and to maintain sufficient Pit-1 expression in a somatotroph after birth, Ret expression is required (Urbano et al, 2000; Japon et al, 2002) . But if a somatotroph produces too much Pit-1 or migrates to areas in which GDNF is present at much lower concentrations, Ret-induced Pit-1 overexpression will kill it. This would further explain why all GH-secreting adenomas maintain normal Ret/GFRa1 and GDNF expression, and why GH-secreting adenomas are unable to metastasize.
